That might be about to shift.
For years, treatment for advanced head and neck cancers has meant heavy hospital routines, brutal side effects and limited hope once first lines of therapy failed. A new under-the-skin injection now hints at a different path, one where control of the disease no longer automatically means weeks strapped to an infusion chair.
A changing cancer and treatments running out of road
Head and neck cancers, often called ENT cancers in Europe, cover tumours of the mouth, throat, larynx, sinuses and nasal cavities. Most are squamous cell carcinomas that start in the thin lining of the upper airways and digestive tract. In the UK alone, around 12,500 people receive this diagnosis every year, and incidence keeps rising in men under 60.
For decades, tobacco and alcohol sat at the centre of the blame. The picture has changed. Human papillomavirus (HPV), especially high‑risk strains such as HPV‑16, now drives a large share of oropharyngeal cancers, often in non‑smokers with no heavy drinking history. This shift creates a younger, more diverse patient group and makes long‑term outcomes harder to predict.
Therapies still rely heavily on surgery, radiotherapy and platinum-based chemotherapy. These approaches can cure early disease, but when cancer spreads or returns, the toolbox shrinks fast. Immunotherapy drugs like pembrolizumab and nivolumab brought genuine progress, yet many patients either never respond or relapse within months.
Targeted therapy has not fixed the problem. Cetuximab, an antibody against the EGFR receptor, offers only modest benefit and helps a fraction of patients. After failure of platinum chemotherapy and immunotherapy, oncologists often reach a therapeutic dead end, where the focus quietly drifts from control to comfort.
For patients who have burned through chemotherapy and immunotherapy, few options remain. Any signal of lasting control matters.
This is where amivantamab, tested in the Orig‑AMI 4 trial led by the Institute of Cancer Research in London and the Royal Marsden NHS Foundation Trust, enters the scene.
What makes amivantamab different
Amivantamab belongs to a new generation of “bispecific” antibodies. Instead of locking onto a single target, it binds to two different receptors at once and also draws immune cells into the fight. That triple action sets it apart from older targeted drugs.
Hitting EGFR and MET at the same time
The first pillar of its action is EGFR, the epidermal growth factor receptor. Many head and neck tumours overexpress EGFR, which acts as a growth pedal for cancer cells. Blocking EGFR slows cell division and can make tumours more sensitive to radiation and drugs.
➡️ Here’s everything you need to know about canned sardines
➡️ 3.2 Billion Years Ago, An Asteroid Twice The Size Of Paris Threw Earth Into Chaos
➡️ Discovered in Spain in 1994, the “Excalibur” sword may have Islamic origins
➡️ I tried this skillet apple crumble and now I make it year-round
➡️ How to remove moss from your lawn naturally and effectively ?
➡️ Goodbye hair dyes : the new trend that covers grey hair and helps you look younger
The second target, MET, sits at the heart of another growth and survival pathway. When doctors block EGFR alone, some tumours switch to MET signalling as an escape route. By inhibiting MET as well, amivantamab tries to slam both doors at once, limiting the cancer’s ability to reroute its biology.
Recruiting the immune system as backup
The third mechanism involves the patient’s own immune system. The backbone of the antibody can latch onto natural killer (NK) cells and other immune effectors. Once attached, these cells recognise the coated tumour cells and attack them directly, a process called antibody‑dependent cellular cytotoxicity.
Amivantamab does more than just block growth signals; it turns cancer cells into targets that immune cells can see and destroy.
This layered strategy helps explain why doctors are seeing relatively quick responses, even in heavily pre‑treated patients whose cancers have already outsmarted multiple drugs.
A simple injection with complex effects
Most monoclonal antibodies arrive through long intravenous infusions. Patients travel to hospital, sit connected to drip lines, and spend hours under observation. Amivantamab in this trial comes as a subcutaneous injection, given just under the skin.
This method offers several practical advantages:
- Shorter chair time and less time in hospital
- Lower burden on infusion units already running at capacity
- Potential for administration in outpatient clinics or, one day, at home
- Fewer devices such as central lines or ports, which can get infected or clot
For patients who may face treatment for months, sometimes years, the shift from infusion to injection changes daily life. It opens up space for work, family roles and travel that standard chemotherapy often shuts down.
Inside the Orig‑AMI 4 trial
The Orig‑AMI 4 study enrolled 86 people with recurrent or metastatic head and neck squamous cell carcinoma. Every participant had already received platinum chemotherapy and a checkpoint inhibitor, with their cancer either progressing or returning afterwards.
Researchers gave amivantamab alone, without combination chemotherapy, and watched for changes in tumour burden and disease progression. Interim data presented at the ESMO 2025 congress in Berlin caught attention across the oncology community.
Around 76% of patients saw their tumours shrink or at least stop growing, typically within six weeks of starting the injection.
For such a heavily pre-treated population, that figure stands out. Many oncologists would usually expect far lower control rates at this stage of disease.
What the early numbers show
| Trial feature | Reported outcome |
|---|---|
| Number of patients | 86 |
| Previous treatments | Platinum chemotherapy + immunotherapy, both failed |
| Tumour control (shrink or stable) | 76% of patients |
| Time to first response | About 6 weeks on average |
| Median progression‑free survival | 6.8 months |
| Still on treatment (July 2025) | 62% (53 out of 86) |
Progression‑free survival of 6.8 months may not sound long outside oncology, but for patients who have already failed two major treatment lines, it compares favourably with historical expectations.
Side effects remain a key question with any targeted drug. In this trial, most adverse events were mild to moderate, with skin reactions at the top of the list. Compared with classic chemotherapy—known for hair loss, nausea, infections and nerve damage—the safety profile appears more manageable, although longer-term data will matter.
Shifting focus toward quality of life
The trial also reflects a deeper change in cancer care: doctors now weigh quality of life alongside response rates and survival curves. A treatment that keeps a patient out of hospital, preserves speech and swallowing and allows social life to continue may carry more value than a slightly more powerful drug that wipes them out physically.
The story of one British patient, 59-year-old Carl Walsh, illustrates this trend. Diagnosed with tongue cancer in 2024, he went through two lines of standard therapy that failed to control the disease. After joining the amivantamab trial in London, he received seven cycles of the injection. He reported marked symptom relief and a return to almost normal eating and speaking, with only limited skin issues instead of the crippling side effects he had braced for from chemotherapy.
When patients say they sometimes forget they have cancer, that signals more than tumour shrinkage; it hints at a different daily reality.
Clinicians involved in the research argue that this patient‑centred angle should guide future development. A drug that delivers decent tumour control with tolerable toxicity and easy logistics can reshape care pathways, especially in public health systems under pressure.
What needs to happen next
Despite all the enthusiasm, these are still early‑phase results from a relatively small cohort. The next test will be phase III trials comparing amivantamab directly with current standards, alone or in combination with chemotherapy or immunotherapy. Such studies will define whether health systems like the NHS adopt the drug widely and under what conditions.
Regulators will examine not only response rates and survival, but also long‑term side effects, impact on daily functioning and cost‑effectiveness. Bispecific antibodies tend to be expensive to manufacture, and payers will ask hard questions about which patients benefit most and at what stage of disease.
Beyond head and neck cancer
Amivantamab already holds approval in non‑small cell lung cancer with specific EGFR alterations. Researchers now look at whether the same EGFR/MET and immune‑engaging strategy may help in other tumours that share similar pathways, such as some oesophageal and colorectal cancers linked to abnormal EGFR signalling.
This raises a broader point for patients and clinicians: many modern cancer drugs no longer belong to a single organ site. Instead they target molecular patterns. A medicine born in lung cancer can end up in ENT clinics; a drug trial in bowel cancer may eventually help people with brain metastases. Understanding one’s tumour profile—HPV status, EGFR expression, MET activity—could soon matter as much as the body location of the disease.
What patients should ask their doctors
For anyone living with recurrent or metastatic head and neck cancer, amivantamab will not yet sit on the standard prescription pad. It remains under investigation. Still, the data already shape useful questions during consultations:
- Am I eligible for any clinical trial involving EGFR or MET‑targeted drugs?
- Has my tumour been tested for HPV, EGFR and other relevant biomarkers?
- Which options remain after my current line of treatment, and how do they compare in terms of hospital time and side effects?
- Could subcutaneous antibody therapy become available locally in the near future?
Patients who understand these points can better weigh the trade‑offs between intensive hospital-based therapy and newer approaches that aim to protect both length and quality of life.
For clinicians, amivantamab also raises practical questions about service design. A move from infusion-heavy regimens to injections might free up chemotherapy chairs but increase demand on outpatient nursing and pharmacy preparation. Hospitals may need to recalibrate staffing models, cold‑chain storage and home‑care partnerships if such agents become mainstream.
Finally, the story of this drug illustrates a quieter change in cancer medicine: the shift from blunt, one‑size‑fits‑all regimens to intricate, layered strategies that treat cancer as a moving target. Combining receptor blockade with immune engagement, delivered in a form that fits into daily routine, suggests how future therapies might look—not as miracle cures, but as smarter tools that keep aggressive diseases in check for longer, with less sacrifice from patients’ lives.
Originally posted 2026-03-04 03:30:44.